Diffusion Pharmaceuticals Inc. [NASDAQ: DFFN] jumped around 0.01 points on Thursday, while shares priced at $0.57 at the close of the session, up 2.68%. The company report on July 6, 2021 that DFFN: TSC Causes Dose Dependent Increase in Tissue Oxygenation in TCOM Trial….
By David Bautz, PhD.
Diffusion Pharmaceuticals Inc. stock is now -27.69% down from its year-to-date (YTD) trading value. DFFN Stock saw the intraday high of $0.5999 and lowest of $0.5455 per share. The company’s 52-week high price is 1.85, which means current price is +12.75% above from all time high which was touched on 02/17/21.
Compared to the average trading volume of 1.67M shares, DFFN reached a trading volume of 1844646 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Diffusion Pharmaceuticals Inc. [DFFN]?
H.C. Wainwright have made an estimate for Diffusion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 17, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 21, 2018, representing the official price target for Diffusion Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Diffusion Pharmaceuticals Inc. is set at 0.05 The Price to Book ratio for the last quarter was 0.90, with the Price to Cash per share for the same quarter was set at 0.44.
How has DFFN stock performed recently?
Diffusion Pharmaceuticals Inc. [DFFN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.86. With this latest performance, DFFN shares dropped by -23.92% in over the last four-week period, additionally sinking by -50.44% over the last 6 months – not to mention a drop of -50.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DFFN stock in for the last two-week period is set at 42.19, with the RSI for the last a single of trading hit 45.61, and the three-weeks RSI is set at 41.82 for Diffusion Pharmaceuticals Inc. [DFFN]. The present Moving Average for the last 50 days of trading for this stock 0.6780, while it was recorded at 0.5494 for the last single week of trading, and 0.8478 for the last 200 days.
Diffusion Pharmaceuticals Inc. [DFFN]: Deeper insight into the fundamentals
Diffusion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 22.40 and a Current Ratio set at 22.40.
Insider trade positions for Diffusion Pharmaceuticals Inc. [DFFN]
There are presently around $6 million, or 11.50% of DFFN stock, in the hands of institutional investors. The top three institutional holders of DFFN stocks are: VANGUARD GROUP INC with ownership of 4,120,872, which is approximately 947.955% of the company’s market cap and around 0.18% of the total institutional ownership; BLACKROCK INC., holding 2,044,449 shares of the stock with an approximate value of $1.18 million in DFFN stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $1.05 million in DFFN stock with ownership of nearly -35.58% of the company’s market capitalization.
18 institutional holders increased their position in Diffusion Pharmaceuticals Inc. [NASDAQ:DFFN] by around 6,256,111 shares. Additionally, 9 investors decreased positions by around 1,316,510 shares, while 3 investors held positions by with 2,341,380 shares. The mentioned changes placed institutional holdings at 9,914,001 shares, according to the latest SEC report filing. DFFN stock had 9 new institutional investments in for a total of 599,646 shares, while 7 institutional investors sold positions of 287,610 shares during the same period.